Drug regulators in the EU, the US and Japan are seeking to help streamline the development of antibiotics for patients infected with multi-drug resistant (MDR) bacteria by addressing the difficulties developers face when it comes to conducting randomized clinical trials.
The move is part of the agreement that the European Medicines Agency, the Food and Drug Administration and the Japanese...